Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute, Inc. filings document regulatory disclosures for a Nasdaq-listed Nevada biopharmaceutical company developing ersodetug for hyperinsulinism. Recent Current Reports on Form 8-K include Regulation FD disclosures on the sunRIZE congenital hyperinsulinism program, FDA meeting updates, investor presentations, expanded access data in tumor hyperinsulinism, and exhibits containing related press releases and corporate materials.
The filing record also includes Form 8-K disclosures for quarterly financial results, annual stockholder voting matters, board elections and amendments to executive employment agreements. These documents record the company’s clinical-development communications, governance actions, capital-market disclosures and material corporate agreements.
Rezolute, Inc. (RZLT) reported a new equity compensation grant to one of its directors. On 11/19/2025, the reporting person acquired 21,000 common shares as a grant of restricted stock units at a price of $0, reflecting stock-based compensation rather than a purchase. After this transaction, the director beneficially owned 21,000 common shares directly.
On the same date, the director also received a stock option to buy 12,000 common shares at an exercise price of $10.16 per share, with the option expiring on 11/19/2035. Both the 21,000 restricted stock units and the 12,000 options are scheduled to fully vest on December 1, 2026, tying the director’s compensation to Rezolute’s future share performance.
Rezolute, Inc. reported results from its 2026 annual stockholder meeting. Stockholders elected all seven director nominees to the board, with each receiving a majority of votes cast. As of the record date of September 22, 2025, 90,811,368 shares of common stock were outstanding and 66,700,068 shares were represented at the meeting, establishing a quorum.
Stockholders ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026. A non-binding say-on-pay proposal approving compensation for named executive officers also received stockholder approval. In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan to increase the shares available for issuance from 14,450,000 to 21,950,000. An adjournment proposal related to the equity plan amendment was also approved but was not needed once the amendment passed.
Rezolute, Inc. (RZLT) disclosed that director Young‑Jin Kim received new equity awards on 11/19/2025. He was granted 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he directly beneficially owns 170,950 common shares. In addition, he indirectly beneficially owns 8,423,386 common shares held by Handok, Inc., for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kim was also granted a director stock option to purchase 12,000 common shares at an exercise price of $10.16 per share, with the options fully vesting on December 1, 2026 and expiring on November 19, 2035. These awards increase his potential long‑term equity stake and further align his interests with Rezolute shareholders.
Rezolute, Inc. (RZLT) reported an equity grant to a director. On 11/19/2025, the director received 21,000 restricted stock units of Rezolute common shares at a price of $0, increasing their directly owned common shares to 55,500 after the transaction. The filing also reports a grant of a director stock option for 12,000 common shares at an exercise price of $10.16 per share, expiring on 11/19/2035.
The 21,000 restricted stock units fully vest on December 1, 2026, meaning the director will receive the underlying shares at that time if conditions are met. The 12,000 options become fully exercisable on December 1, 2026, giving the director the right to buy Rezolute shares at $10.16 per share through the expiration date.
Rezolute, Inc. (RZLT) reported an insider equity grant for director Gil M. Labrucherie. On 11/19/2025, he received 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he beneficially owns 55,500 common shares directly and 53,572 common shares indirectly through The Labrucherie Trust dated 9/1/2009.
He was also granted a director stock option for 12,000 common shares at an exercise price of $10.16 per share on 11/19/2025. These options are exercisable until 11/19/2035 and fully vest on December 1, 2026.
Rezolute, Inc. filed an 8-K noting it hosted an investor event and related presentation to provide an update on the Ersodetug development program.
The presentation is furnished as Exhibit 99.1 and is not deemed “filed” under the Exchange Act. The company included customary forward‑looking statements cautions and referred readers to its risk factors in prior SEC filings. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.
Rezolute, Inc. (RZLT) filed its quarterly report, highlighting continued late-stage development of ersodetug and typical clinical-stage losses. The company reported a net loss of $18.2 million for the quarter on operating expenses of $19.8 million. Interest and other income was $1.7 million.
Liquidity remains strong with cash and cash equivalents of $9.1 million and investments in marketable debt securities of $143.1 million as of September 30, 2025. Total assets were $158.7 million and shareholders’ equity was $147.2 million. Management believes existing cash and investments will fund operations for at least 12 months.
Key pipeline updates include the Phase 3 sunRIZE study in congenital hyperinsulinism with topline data anticipated in December 2025, and FDA-agreed modifications to the Phase 3 upLIFT trial in tumor hyperinsulinism to a single-arm, open-label design in as few as 16 participants. Capital actions included an April 2025 underwritten offering with approximately $103.5 million gross proceeds and termination of a $50.0 million at-the-market program in October 2025. As of November 4, 2025, 92,727,532 common shares were outstanding.
Rezolute, Inc. (RZLT) furnished an 8‑K announcing it issued a press release with financial results for the first quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.
Rezolute, Inc. reported two corporate actions. The company amended employment agreements for its CEO Nevan C. Elam, CMO Brian Roberts, CFO Daron Evans, and CCO Sunil Karnawat to provide a full gross-up payment for any excise tax and related taxes arising from “excess parachute payments” in a change of control under Section 280G. The company will determine the gross-up amount in its sole discretion, and the amendments will be filed with the next Form 10-Q.
Rezolute also delivered written notice to terminate its Open Market Sale Agreement with Jefferies LLC, effective October 24, 2025. The agreement supported an at-the-market program established under a November 2023 S-3 shelf. The company states it did not undertake any sales under the at-the-market program.
Rezolute, Inc. is asking shareholders to vote at the Annual Meeting on a slate of routine corporate matters including election of seven director nominees, ratification of Grant Thornton LLP as independent auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2021 Equity Incentive Compensation Plan to increase available shares from 14,450,000 to 21,950,000. The proxy materials will be delivered primarily via internet starting on or about October 10, 2025 to stockholders of record as of the September 22, 2025 record date. The 2021 Equity Plan summary states the plan covers a variety of award types including options, SARs, restricted stock, RSUs, dividend equivalents and other stock-based awards and describes standard change-in-control and replacement provisions. The company discloses a Clawback Policy that permits recovery of incentive compensation for up to three years prior to a required financial restatement and states the Compensation Committee administers that policy and the 2021 Equity Plan.